Plasma Cell Myeloma Refractory

Oncology

20 drugs in development·2 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
belumosudil	Sanofi (SNY)
carfilzomib	Sanofi (SNY)
Isatuximab	Sanofi (SNY)
montelukast	Sanofi (SNY)
Montelukast	Sanofi (SNY)

Phase 2(4)

Drug	Company
diphenhydramine	Sanofi (SNYNF)
isatuximab	Sanofi (SNY)
isatuximab sc-obds	Sanofi (SNY)
sar446523	Sanofi (SNYNF)

Phase 1(2)

Drug	Company
sar439459	Sanofi (SNY)
sar446523	Sanofi (SNY)

Phase 1/Phase 2(7)

Drug	Company
belantamab mafodotin	Sanofi (SNYNF)
belantamab mafodotin	Sanofi (SNY)
evorpacept	Sanofi (SNY)
evorpacept	Sanofi (SNYNF)
pegenzileukin	Sanofi (SNYNF)
pegenzileukin	Sanofi (SNY)
sar439459	Sanofi (SNYNF)

Phase 4(2)

Drug	Company
Belumosudil	Sanofi (SNY)
Belumosudil mesylate	Sanofi (SNY)

Compare drugs

belumosudil vs carfilzomib belumosudil vs Isatuximab belumosudil vs montelukast

Frequently asked questions

How many drugs are in development for Plasma Cell Myeloma Refractory?

BioSniper tracks 20 drugs in development for Plasma Cell Myeloma Refractory across 2 companies.

How many clinical trials target Plasma Cell Myeloma Refractory?

There are 3 clinical trials targeting Plasma Cell Myeloma Refractory tracked by BioSniper.

Deep-dive into Plasma Cell Myeloma Refractory

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Plasma Cell Myeloma Refractory — Drugs in Development & Clinical Trials | BioSniper